首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到20条相似文献,搜索用时 78 毫秒
1.
氯化镓治疗去卵巢大鼠骨质疏松的实验观察   总被引:2,自引:0,他引:2  
目的 探讨镓对去卵巢大鼠骨质疏松的治疗作用。方法 通过切除大鼠卵巢建立骨质疏松模型,经氯化镓治疗12周后,用单光子法测量骨密度;放免法检测相关血清学指标;测定骨病理形态学指标。结果 氯化镓治疗组血清抗酒石酸酸性磷酸酶、骨小梁间距低于骨质疏松对照组,而骨密度和骨小梁宽度高于骨质疏松对照组。结论 镓对去卵巢所致大鼠的骨质疏松有效。  相似文献   

2.
氯化镓对去卵巢大鼠NO、IL-6、 TNFα影响的实验研究   总被引:1,自引:0,他引:1  
目的 研究氯化镓对去卵巢大鼠一氧化氮、白细胞介素-6、肿瘤坏死因子α的影响,探讨氟化镓影响去卵巢大骨代谢的作用机理。方法 通过切除大鼠卵巢建立骨质疏松模型,经氯化镓治疗12周后,用生化、放免法检测血清一氧化氮、白细胞介素-6、肿瘤坏死因子α及其它相关指标;单光子法测量骨密度;测定骨病理形态学指标。结果 氯化镓治疗组与骨质疏松对照组相比,血清一氧化氮升高,肿瘤坏死因子α降低,骨质疏松状况得到改善。结论 氯化镓抗骨质疏松作用可能与其对一氧化氮、肿瘤坏死因子α等因子的调节有关。  相似文献   

3.
目的探讨硒对硝酸镓治疗骨质疏松的骨镓沉积的阻止作用。方法将骨组织溶于盐酸溶液,处理后在波长557.0 nm测定其吸光度以计算含镓量,在422.7 nm测定其吸光度以计算含钙量;用钼蓝比色法测定含磷量:用材料试验机作三点弯曲试验测定骨强度。结果骨质疏松组与对照组相比,骨钙、磷均有明显下降。硝酸镓治疗组骨含镓量明显升高,但镓硒联合治疗组骨含镓量明显低于单纯硝酸镓治疗组。结论硒对硝酸镓治疗骨质疏松的骨镓沉积有阻止作用。  相似文献   

4.
目的探讨硝酸镓对雌性大鼠切除卵巢后所致骨质疏松的作用机制。方法 8月龄的雌性SD大鼠随机分为实验组和正常对照组。实验组切除双侧卵巢建立骨质疏松动物模型,实验组分为硝酸镓治疗组和骨质疏松组。硝酸镓治疗组:建模成功后,给予1mg/kg硝酸镓腹腔注射,3次/周。骨质疏松组给予生理盐水腹腔注射。正常对照组给予生理盐水腹腔注射。干预3个月后,分别观察各组大鼠胫骨上段结构和检测血清IL-6、骨钙素水平。结果硝酸镓治疗组胫骨上段骨小梁宽度和骨皮质厚度明显高于骨质疏松组(P<0.05),血清IL-6和骨钙素水平与骨质疏松组及正常对照组比较显著增加(P<0.05)。结论硝酸镓对卵巢切除所致的骨质疏松症有明显的治疗作用,其机制可能是通过降低IL-6表达、增加成骨细胞活性,从而达到治疗骨质疏松的作用。  相似文献   

5.
参茸补血丸对去卵巢大鼠骨质疏松防治作用的实验研究   总被引:4,自引:0,他引:4  
目的研究以补肾养血为主的中药参茸补血丸防治骨质疏松的药效学基础,为临床应用提供实验依据。方法清洁级雌性SD大鼠,4.5月龄,体重260~300g,采用手术去除双侧卵巢方法。建立骨质疏松实验动物模型,随机分组。实验药物为参茸补血丸,对照药使用戊酸雌二醇(E2)、钙而奇D600,给药12W。测定骨密度、骨生物力学以及骨代谢相关指标。结果模型组下肢离体股骨、股骨头骨密度显著下降,股骨骨生物力学指标均显著下降,钙、镁代谢平衡异常。子宫指数显著下降,表明实验动物模型成立。与雌激素、钙而奇D作用相似,参茸补血丸具有明显增强股骨、股骨头骨密度,明显改善骨生物力学性能,明显降低抗酒钉酸酸性磷酸酶,明显增加骨钙含量;参茸补血丸+钙而奇D600实验组可明显增加骨钙素含量等防治作用。结论参茸补血丸对防治骨质疏松症具有良好的效果。  相似文献   

6.
金乌骨通胶囊对去卵巢大鼠骨质疏松症预防作用的研究   总被引:2,自引:0,他引:2  
6月龄SD雌性大鼠60只,随机分成6组.用手术切除卵巢方法制造骨质疏松模型,术后按组别给药,12周后处死,分别测定股骨骨密度、骨生物力学水平以及血清生化指标并作统计学分析.发现金乌骨通胶囊可增加大鼠骨密度,改善骨生物力学性能和血清生化指标.提示金乌骨通胶囊可以预防大鼠骨质疏松症的发生.  相似文献   

7.
目的观察补肾健骨汤对去卵巢大鼠骨质疏松症骨密度和骨生物力学性能的影响。方法将90只6月龄雌性Wistar大鼠[体重(300±20)g]随机分为空白对照组15只,造模组(OVX)75只。造模组造模成功后再将其随机分为5组,即模型对照组15只,补肾健骨汤高剂量组15只,补肾健骨汤中剂量组15只,补肾健骨汤低剂量组15只,雌激素组15只。复制骨质疏松症动物模型,造模成功后,分组给药。给药3个月后所有动物统一处死取材。结果 (1)与空白对照组比较,模型对照组股骨骨密度值及骨矿物含量有明显下降(P0.05);与模型对照组相比,补肾健骨汤中高剂量组与雌激素组的骨密度及骨矿盐含量均有明显提高(P0.05),补肾健骨汤组高剂量组与雌激素组无明显差异。(2)补肾健骨汤高剂量组和模型对照组相比,大鼠股骨的弹性模量、最大载荷、屈服强度均有不同程度的改善,差异有统计学意义(P0.05),与空白对照组相比差异无统计学意义(P0.05)。结论去卵巢大鼠骨密度及骨矿物含量明显降低;补肾健骨汤能明显改善去卵巢大鼠骨密度及骨矿物含量和骨生物力学性能。  相似文献   

8.
氯化锂(lithium chloride,LiCl)在治疗精神疾病方面已经安全有效地使用了半个多世纪.近年来,LiCl在抗骨质疏松症中的作用逐渐得到证实.本文综述LiCl对促进骨形成并改善骨骼质量的效果,如LiCl可对成骨细胞(osteoblast,OB)增殖和分化产生影响进而调控OB的生长发育,且能够减少破骨细胞(o...  相似文献   

9.
以补肝肾、填精髓的中药骨灵丸进行防治原发性骨质疏松症(OP)的动物实验研究。通过制作原发性OP大鼠模型,并观测骨密度、骨生物力学、骨组织形态计量学指标,以观察骨灵丸疗效并探讨其主要作用机制。结果显示大鼠去势后出现高转换型OP,而骨灵丸能够有效对抗去势大鼠出现的骨丢失,维护鼠骨强度、弹性,保持骨生物力学性能,可使过高的破骨细胞(OC)活性降低,使骨吸收、骨形成二者之间偶联趋于平衡,从而有效地维持了鼠骨密度。研究结果显示骨灵丸是一个有前途的防治OP新药,值得进一步深入研究。  相似文献   

10.
目的 探讨补肾中药复方对去卵巢骨质疏松模型大鼠皮质骨 (股骨 )生物力学性能的作用及其相关的机制。方法 将 50只 1 0月龄Wistar雌性大鼠随机分为 5组 ,每组 1 0只。正常对照组做假手术 ,其余 4组做卵巢切除术。术后正常饲养 90 d,第 91天开始给药 ,连续用药 90 d,处死 ,测定股骨的骨矿密度、几何尺寸和股骨的生物力学性能。结果 模型大鼠股骨的生物力学性能明显下降 ,骨强度降低 ;股骨干外径变细 ,股骨中段骨皮质面积减少 ,骨矿密度有所下降。补肾中药复方组 (密骨胶囊组和仙灵骨葆组 )大鼠股骨的生物力学性能明显提高 ,骨强度增加 ;股骨中段外径增粗 ,骨皮质面积增加 ,骨矿密度提高。结论 补肾中药复方通过提高去卵巢骨质疏松模型大鼠皮质骨 (股骨 )的宏观结构生物力学应答机能 ,明显改善其生物力学性能。  相似文献   

11.
12.
目的 :通过动物实验研究 ,客观地评价妪松康的防治效果 ,探讨其作用机理。方法 :采用去卵巢大鼠作为绝经后骨质疏松症的动物模型。 5 0只 3月龄雌性SD大鼠 ,随机分取 10只为假手术对照组 (SO组 ) ,其余大鼠摘取双侧卵巢并随机分为 4组 :模型组 (OVX组 ,n =8只 )、妪松康高剂组 (YH组 ,n =10只 )、妪松康低剂组 (YL组 ,n =10只 )、阳性对照仙灵骨葆组 (XL组 ,=10只 )。药物喂养 13周后处死。结果 :与OVX组比较 ,三治疗组血清E2 、P明显升高(P <0 .0 5 ) ,YH组、XL组股骨BMD升高 (P <0 .0 5 ) ,同时 ,YH组大鼠CT亦明显升高 (P <0 .0 5 ) ,子宫重增加 (P <0 .0 5 )、体重降低 (P <0 .0 5 )并均接近SO组 ,其结果优于XL组和YL组。结论 :妪松康能调节大鼠体内的激素水平 ,对骨骼有雌激素样的保护作用 ,对绝经后骨质疏松症有一定的防治作用  相似文献   

13.
本文采用形态计量学的方法观察了尼尔雌醇防治由雌激素缺乏所致的骨质疏松症的效果。结果表明,正常对照组与切除卵巢组骨皮质等效厚度、钙盐沉积带等效厚度等主要指标均差别显著,而切除卵巢后加服尼尔雌醇的两组均与正常对照组无明显差别,说明尼尔雌醇可以起到防治骨质疏松症的效果。  相似文献   

14.
为观察镓盐对维甲酸致大鼠骨质疏松动物模型血中碱性磷酸酶 (AL P)和抗酒石酸酸性磷酸酶 (TRAP)水平及其变化趋势 ,选用 3月龄 SD雌性大鼠 45只 ,随机分为两组 :正常组 (13只 )和骨质疏松组 (32只 ) ,骨质疏松组按 85 mg/ kg· d维甲酸灌胃 15天 ,然后进入治疗阶段。实验分为四组 :正常组 (6只 ) ,骨质疏松组 (6只 ) ,正常喂养 ;氯化镓治疗组 (9只 ) ,2 5 mg/ kg·d氯化镓灌胃 ;雌激素治疗组 (6只 ) ,雌激素 0 .2 μg/ kg,3次 /周 ,腹腔注射 ,治疗两个月。结果显示模型期骨质疏松组 AL P和 TRAP显著升高 ,镓盐治疗后 AL P和 TRAP降低 ,与正常组接近 ,提示镓盐能抑制破骨细胞活性 ,降低骨转化率。  相似文献   

15.
目的探讨异丙肾上腺素引起的心肌纤维化和比索洛尔对其抑制作用。方法52只Wistar(WS)大鼠随机分为3组:(1)异丙肾上腺素组20只,腹部皮下注射异丙肾上腺1mg/Kg/d;(2)比索洛尔组20只,预先用比索洛尔2mg/Kg/d灌胃,3天后加用异丙肾上腺素1mg/Kg/d皮下注射;(3)对照组12只,腹部皮下注射生理盐水1ml/d。3组均连续腹部皮下注射10天。第15天杀死全部大鼠,分别计算出每只大鼠的心室/体重指数;心室胶原蛋白浓度。结果与对照组相比,异丙肾上腺素组心室/体重指数为6.28±1.10mg/g,明显增加(P<0.01);心室组织胶原蛋白浓度为8.717±0.795ng/mg,明显升高(P<0.05)。与异丙肾上腺素组相比,比索洛尔组心室/体重指数为5.53±0.87mg/g,心室组织胶原蛋白浓度为7.897±0.107ng/mg,均明显下降(P<0.05)。结论大剂量异丙肾上腺素可引起大鼠心肌纤维化,比索洛尔可以有效抑制这一过程。  相似文献   

16.

Background

The United States Preventive Services Task Force recommends universal osteoporosis screening among women ages 65+ and targeted screening of younger women, but historically, adherence to these evidence-based recommendations has been suboptimal.

Methods

To describe contemporary patterns of osteoporosis screening, we conducted a retrospective analysis using the OptumLabs? Data Warehouse, a database of de-identified administrative claims, which includes medical and eligibility information for over 100 million Medicare Advantage and commercial enrollees. Study participants included 1,638,454 women ages 50+ with no prior history of osteoporosis diagnosis, osteoporosis drug use, or hip fracture. Osteoporosis screening during the most recent 2-year period of continuous enrollment was assessed via medical claims. Patient sociodemographics, comorbidities, and utilization of other services were also determined using health insurance files.

Results

Overall screening rates were low: 21.1%, 26.5%, and 12.8% among women ages 50-64, 65-79, and 80+ years, respectively. Secular trends differed significantly by age (P <.001). Between 2008 and 2014, utilization among women ages 50-64 years declined 31.4%, changed little among women 65-79, and increased 37.7% among women 80+ years. Even after accounting for socioeconomic status, health status, and health care utilization patterns, non-Hispanic black women were least likely to be screened, whereas non-Hispanic Asian and Hispanic women were most likely to undergo screening. Marked socioeconomic gradients in screening probabilities narrowed substantially over time, decreasing by 44.5%, 71.9%, and 59.7% among women ages 50-64, 65-79 and 80+ years, respectively.

Conclusions

Despite significant changes in utilization of osteoporosis screening among women ages 50-64 and 80+, in line with national recommendations, tremendous deficiencies among women 65+ remain.  相似文献   

17.
PURPOSE Previous studies have shown dietary supplements of vitamin E to reduce the incidence of postoperative peritoneal adhesions. The objective of this study was to show the effect of intramuscular or intraperitoneal administration of vitamin E on peritoneal adhesions.METHODS Eighty rats were divided into four groups: Group A (control), Group B (intramuscular vitamin E), Group C (intraperitoneal olive oil, the vehicle/diluent of vitamin E), and Group D (intraperitoneal vitamin E diluted in olive oil). The same experimental method was used in all rats to produce adhesions, consisting of cecal abrasion and ligature of the adjacent parietal peritoneum. The rats were killed at 14 days to assess the adhesions occurring. The results were analyzed using a chi-squared test.RESULTS All animals in Groups A, B, and C had substantial adhesions. In Group D, 11 rats had insubstantial adhesions and only 4 had substantial adhesions. There were no significant differences between Groups A, B, and C in terms of percent formation of adhesions. A significant difference was found between Group D (vitamin E plus olive oil by the intraperitoneal route) and each of the experimental groups, A, B, and C (P < 0.0005).CONCLUSIONS Our results show that intraperitoneal administration of vitamin E just before closing the laparotomy was effective for reducing adhesion formation. By contrast, the same effect was not achieved after intramuscular administration.  相似文献   

18.
19.
茶色素对兔实验性动脉粥样硬化的预防作用   总被引:12,自引:1,他引:12  
为探讨茶色素对高胆固醇兔动脉粥样硬化的影响 ,将 2 4只新西兰雄性白兔按血脂水平随机分为对照组、茶色素低剂量组 [32 μg (g·d) ]和高剂量组 [96 μg (g·d) ],每组 8只 ,实验期间均以高胆固醇饮食。喂养 8周后处死动物 ,测定血脂水平、血浆内皮素水平和斑块面积比。结果发现 ,实验 4周及 8周后血清总胆固醇和甘油三酯水平明显高于实验前 ,但三组间没有明显差异。实验 8周后对照组、茶色素低剂量组和高剂量组血浆内皮素水平分别为 775 .5 8± 6 6 8.72 μg L、2 5 1.73± 2 41.5 7μg L和 6 5 .43± 17.18μg L。与对照组相比 ,茶色素低剂量组内皮素水平有所降低 ,但无显著性差异 (P >0 .0 5 ) ,茶色素高剂量组内皮素水平明显降低 (P <0 .0 5 )。对照组、茶色素低剂量组和高剂量组动物胸主动脉斑块面积百分比分别为 0 .793± 0 .0 77、0 .5 88± 0 .2 0 5和 0 .437± 0 .116 ,内膜面积与中膜面积百分比分别为 0 .6 2 5± 0 .2 0 6、0 .32 6± 0 .2 76和 0 .175± 0 .0 92 ,茶色素组斑块面积明显低于对照组 (P <0 .0 5 )。结果提示 ,茶色素能够防止兔实验性粥样斑块的形成 ,并降低血浆内皮素水平  相似文献   

20.
This study evaluated the extracellular matrix (collagen and elastic fibers) in pleurodesis induced by intrapleural talc (TL) or silver nitrate (SN). Study subjects were 420 rabbits divided into two groups and sacrificed from 15 min to 12 months after the injection of the sclerosing agents at intervals previously defined. Pleural adhesions and fibrosis were graded (0-4), and the collagen and elastin were quantified. The maximum score of the pleural adhesions was observed two months after TL (2.80 +/- 0.99) and 15 days after SN (3.75 +/- 0.25). More intense pleural adhesions were observed in the SN group from day 5 (p < 0.05). Pleural thickness and pleural fibrosis were, in general, significantly higher after SN (p < 0.05). Increased deposition of collagen and elastin was observed in both groups but was more evident in the SN group. In the TL group, a linear correlation was observed between pleural adhesions and fibrosis (r = 0.775), between pleural adhesions and collagen (r = 0.779), and between fibrosis and collagen (r = 0.709). In the SN group, these correlations were acceptable (r = 0.605, 0.665, and 0.663). The elastin presented a correlation of 0.707 (p < 0.001) in the TL group and of 0.564 (p < 0.001) in the SN group. In conclusion, intrapleural 0.5% silver nitrate and talc (400 mg/kg) are effective in the induction of pleurodesis. However, the intensity of adhesions and the richness of collagen after SN, in combination with the early onset of tissue remodeling, demonstrate the local superiority of this agent. Considering the easy availability and instillation, the low cost, and the absence of important side effects, silver nitrate might be considered as a sclerosing agent to induce pleurodesis in humans.  相似文献   

设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号